Intellia Therapeutics Inc. (NASDAQ: NTLA) announced positive results from its phase 3 HAELO trial of lonvoguran ziclumeran for hereditary angioedema ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE